NCT05379595 2026-04-13
OrigAMI-1
Janssen Research & Development, LLC
Phase 1/2 Recruiting
Clinical Trials
35 trialsNCT05919264 2026-04-09
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT04083599 2026-04-08
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT05846867 2026-03-04
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
Akeso
Phase 1/2 Active not recruiting
NCT07391566 2026-02-06
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
Luye Pharma Group Ltd.
Phase 1/2 Not yet recruiting
NCT04421820 2026-01-27
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06428409 2026-01-22
MK-9999-02A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04689347 2026-01-12
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 1/2 Recruiting
NCT06385925 2025-12-15
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2 Recruiting
NCT05627635 2025-11-10
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT03184870 2025-10-09
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05609370 2025-10-02
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
BeiGene
Phase 1/2 Active not recruiting
NCT03314935 2025-08-12
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT03169777 2025-02-21
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03563157 2024-12-11
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03337087 2024-05-17
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Academic and Community Cancer Research United
Phase 1/2 Active not recruiting
NCT01133990 2023-11-07
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Eisai Inc.
Phase 1/2 Terminated
NCT05116891 2023-07-03
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
Phase 1/2 Completed
NCT03085914 2022-09-23
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
Phase 1/2 Completed
NCT02244632 2020-09-09
Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer
Isofol Medical AB
Phase 1/2 Completed
NCT02568046 2019-03-26
Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
Symphogen A/S
Phase 1/2 Terminated
NCT01047293 2017-04-04
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
University of Utah
Phase 1/2 Completed
NCT02785068 2017-01-11
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
Merrimack Pharmaceuticals
Phase 1/2 Withdrawn
NCT00244348 2015-08-27
Hepatic Artery Infusion With Oxaliplatin
Medical College of Wisconsin
Phase 1/2 Withdrawn
NCT00494221 2014-03-27
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
AstraZeneca
Phase 1/2 Completed
NCT00030342 2013-06-26
Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00049101 2013-06-24
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00016133 2013-05-30
Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00055822 2012-07-04
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Phase 1/2 Completed
NCT00291785 2011-06-08
Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer
CTI BioPharma
Phase 1/2 Completed
NCT00005050 2011-03-28
Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer
NYU Langone Health
Phase 1/2 Completed
NCT00166465 2011-03-14
Stage IV Colorectal CA ALIMTA
Mayo Clinic
Phase 1/2 Completed
NCT00478946 2009-01-21
A Study of Picoplatin in Colorectal Cancer
Poniard Pharmaceuticals
Phase 1/2 Unknown
NCT00003001 2008-07-24
Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00209625 2005-09-21
Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer
Hokkaido Gastrointestinal Cancer Study Group
Phase 1/2 Completed